|
Status |
Public on Dec 19, 2012 |
Title |
LPSX3 Xenograft passage 1 |
Sample type |
RNA |
|
|
Channel 1 |
Source name |
Mixed reference pool of fatty tumors
|
Organism |
Homo sapiens |
Characteristics |
reference: total RNA from human 8 benign fatty tumors (7 lipomas, 1 hibernoma), 33 well differentitated liposarcoma, 15 de-differentiated liposarcoma, 2 pleomorphic liposarcoma, and 11 myxoid liposarcomas
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using QIAzol RNA Kit following manufacturer's instructions
|
Label |
Cy3
|
Label protocol |
Using Agilent Quick Amp Labeling Kit (Agilent Technologies) and protocol
|
|
|
Channel 2 |
Source name |
LPSX3 Xenograft passage 1
|
Organism |
Homo sapiens |
Characteristics |
tissue type: xenograft cell type: liposarcoma tumor histology: de-differentiated host organism: Mus musculus
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using QIAzol RNA Kit following manufacturer's instructions
|
Label |
Cy5
|
Label protocol |
Using Agilent Quick Amp Labeling Kit (Agilent Technologies) and protocol
|
|
|
|
Hybridization protocol |
Following Agilent Human 44K microarray processing protocol
|
Scan protocol |
Scanned on an Agilent Scanner
|
Description |
Xenograft tumor of LPSX3 at passage 1
|
Data processing |
Agilent Feature Extraction software v.7.5 was used to calculate gene expression values. For multiple spots representing each unique probe, the average of their intensity ratios (log10 of Cy5/Cy3) was used to represent the probe.
|
|
|
Submission date |
Dec 18, 2012 |
Last update date |
Dec 19, 2012 |
Contact name |
Linh My Tran |
E-mail(s) |
linhtran@ucla.edu
|
Organization name |
University of Los Angeles
|
Department |
Medicine - Pulmonary & Critical Care
|
Lab |
Dubinett Lab
|
Street address |
Box 951690, 37-131 CHS
|
City |
Los Angeles |
State/province |
California |
ZIP/Postal code |
90095-1690 |
Country |
USA |
|
|
Platform ID |
GPL6480 |
Series (1) |
GSE42975 |
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down regulation as a malignant signature and response to PI3K pathway inhibition |
|